From GlobeNewswire: 2025-02-25 07:00:00

Beam Therapeutics Inc. achieved adult enrollment target for BEACON trial of BEAM-101 for sickle cell disease patients. Phase 1/2 trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency to provide initial data by mid-2025. Dosing for Phase 1/2 trial of BEAM-301 in Glycogen Storage Disease Type 1a expected to start in early 2025. IND-enabling studies for ESCAPE approach ongoing, BEAM-103 healthy volunteer study to start by year-end. Ended Q4 2024 with $850.7M in cash, supporting plans into 2027.

Beam Therapeutics reported progress in BEACON trial for BEAM-101, enrolling adult and adolescent sickle cell disease patients. Positive results included increased fetal hemoglobin, reduced sickle hemoglobin, and normalized markers of hemolysis. Initial data from BEAM-302 Phase 1/2 trial in Alpha-1 Antitrypsin Deficiency expected in H1 2025. ESCAPE platform showed potential in non-human primate trials. BEAM-301 Phase 1/2 trial for GSD1a progressing with dosing expected in early 2025.

Financially, Beam Therapeutics ended Q4 2024 with $850.7M in cash. R&D expenses were $101.4M for Q4 2024, $367.6M for full year 2024. G&A expenses were $28.7M for Q4 2024, $111.5M for full year 2024. Net loss was $90.4M for Q4 2024, $376.7M for full year 2024. Cash runway expected to cover operating expenses into 2027.

Beam Therapeutics anticipates key milestones in 2025, including updated data from BEACON trial for BEAM-101 by mid-2025. Dosing of 30 patients in BEACON trial by mid-2025. Phase 1 healthy volunteer trial of BEAM-103 to start by end of 2025. Initial data from BEAM-302 Phase 1/2 trial in AATD expected in H1 2025. Dosing for BEAM-301 Phase 1/2 trial in GSD1a to begin in early 2025.



Read more at GlobeNewswire:: Beam Therapeutics Reports Fourth Quarter and Year-End 2024